Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | AOC2 | O75106 | 5/20 | 0.41 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL11335086 | 0.94 | HRH3 (0.46) | HRH3AOC2MAOAMAOBDAO | |
| Bicarbonate SCHEMBL8124381 | 0.91 | GPBAR1 (0.44) | HRH3AOC2MAOAMAOBDAO | |
| Bicarbonate SCHEMBL8116427 | 0.91 | GPBAR1 (0.44) | HRH3AOC2MAOAMAOBDAO | |
| SCHEMBL13638405 | 0.85 | HRH3 (0.47) | HRH3AOC2MAOAMAOBDAO | |
| SCHEMBL10366459 | 0.82 | HRH3 (0.44) | HRH3AOC2MAOAMAOBDAO | |
| SCHEMBL6051185 | 0.81 | CA2 (0.55) | CA2 | |
| SCHEMBL27574307 | 0.81 | HRH3 (0.37) | HRH3AOC2MAOAMAOBDAO | |
| SCHEMBL14271049 | 0.81 | CA2 (0.55) | CA2 | |
| SCHEMBL2059453 | 0.80 | GRM2 (0.44) | HRH3 | |
| SCHEMBL6723015 | 0.80 | HRH3 (0.53) | HRH3AOC2MAOAMAOBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717886-B2 | Ink composition, method for producing organic semiconductor element, organic semiconductor device, and method for producing optical element | SEIKO EPSON CORPORATION (JP) | 2020-07-21 | — | — | US | claimed |
| US-20180030296-A1 | INK COMPOSITION, METHOD FOR PRODUCING ORGANIC SEMICONDUCTOR ELEMENT, ORGANIC SEMICONDUCTOR DEVICE, AND METHOD FOR PRODUCING OPTICAL ELEMENT | SEIKO EPSON CORPORATION (JP) | 2018-02-01 | — | — | US | claimed |
| EP-1891034-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-27 | — | — | EP | claimed |
| EP-1877393-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-01-16 | — | — | EP | claimed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | claimed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | claimed |
| WO-2007076157-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| EP-0824531-A1 | METHOD FOR PREPARING AN OPTICALLY PURE BENZOFURAN CARBOXYLIC ACID AND USE THEREOF FOR PREPARING EFAROXAN | PIERRE FABRE MEDICAMENT (FR) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035682-A1 | METHOD FOR PREPARING AN OPTICALLY PURE BENZOFURAN CARBOXYLIC ACID AND USE THEREOF FOR PREPARING EFAROXAN | PIERRE FABRE MEDICAMENT (FR) | 1996-11-14 | — | — | WO | claimed |
| EP-0008752-B1 | PROCESS FOR THE PREPARATION OF 2,3-DIHYDRO-2-ETHYL-BENZOFURAN-5-ACETIC ACID | ALFA FARMACEUTICI S.p.A. (IT) | 1981-08-12 | — | — | EP | claimed |
| EP-0008752-A1 | Process for the preparation of 2,3-dihydro-2-ethyl-benzofuran-5-acetic acid | ALFA FARMACEUTICI S.p.A. (IT) | 1980-03-19 | — | — | EP | claimed |
| US-20260080976-A1 | SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES | PURDUE RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10717886-B2 | Ink composition, method for producing organic semiconductor element, organic semiconductor device, and method for producing optical element | SEIKO EPSON CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| US-4341792-A | ANTIDIABETIC AND CARDIOTONIC AGENTS | PFIZER INC. (US) | 1982-07-27 | — | — | US | disclosed |
| EP-0008752-B1 | PROCESS FOR THE PREPARATION OF 2,3-DIHYDRO-2-ETHYL-BENZOFURAN-5-ACETIC ACID | ALFA FARMACEUTICI S.p.A. (IT) | 1981-08-12 | — | — | EP | disclosed |
| EP-0008752-A1 | Process for the preparation of 2,3-dihydro-2-ethyl-benzofuran-5-acetic acid | ALFA FARMACEUTICI S.p.A. (IT) | 1980-03-19 | — | — | EP | disclosed |
| EP-0008752-A1 | Process for the preparation of 2,3-dihydro-2-ethyl-benzofuran-5-acetic acid | ALFA FARMACEUTICI S.p.A. (IT) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | HRH3 73/4885AOC2 927/4885MAOA 697/4885 |
| US-20260080976-A1 | SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES | BACE2, ADAM33, SET | HRH3 3103/4885AOC2 4783/4885MAOA 435/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | HRH3 140/4885AOC2 2914/4885MAOA 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.